EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Mizuho Securities Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Buy
November 1, 2023 4:05 PM EDTMizuho Securities analyst Graig Suvannavejh initiates coverage on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) with a Buy rating and a price target of $20.00.
The analyst comments "We initiate on EYPT at Buy/$20 (implies ~200% upside). EYPT is advancing EYP-1901 as a novel treatment for retinal diseases,... More



